PERRIGO
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and… Read more
PERRIGO (PGO) - Net Assets
Latest net assets as of June 2024: €13.29 Million EUR
Based on the latest financial reports, PERRIGO (PGO) has net assets worth €13.29 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€32.27 Million) and total liabilities (€18.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €13.29 Million |
| % of Total Assets | 41.17% |
| Annual Growth Rate | 23.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 158.89 |
PERRIGO - Net Assets Trend (2019–2024)
This chart illustrates how PERRIGO's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PERRIGO (2019–2024)
The table below shows the annual net assets of PERRIGO from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €24.67 Million | -5.65% |
| 2023-06-30 | €26.15 Million | -27.17% |
| 2022-06-30 | €35.91 Million | +320.12% |
| 2019-06-30 | €8.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PERRIGO's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7655168000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €24.67 Million | 100.00% |
| Total Equity | €24.67 Million | 100.00% |
PERRIGO Competitors by Market Cap
The table below lists competitors of PERRIGO ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AQUA BIO TECHNOLOGY NK 4
F:3FZ
|
$6.38K |
|
HUANENG POWER -H-
MU:HUP1
|
$6.38K |
|
MY XUAN BRICK
VN:GMX
|
$6.39K |
|
CHASYS Co. Ltd.
KQ:033250
|
$6.39K |
|
Triad Group PLC
LSE:TRD
|
$6.36K |
|
Ceylon Hospitals PLC
CM:CHLN0000
|
$6.36K |
|
SuperQ Quantum Computing Inc.
F:25X
|
$6.36K |
|
bleuacacia ltd Warrants
NASDAQ:BLEUW
|
$6.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PERRIGO's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,151,032 to 24,674,000, a change of -1,477,032 (-5.6%).
- Net loss of 41,435,000 reduced equity.
- Other factors increased equity by 39,957,968.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-41.44 Million | -167.93% |
| Other Changes | €39.96 Million | +161.94% |
| Total Change | €- | -5.65% |
Book Value vs Market Value Analysis
This analysis compares PERRIGO's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.36x to 3.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-06-30 | €0.20 | €0.47 | x |
| 2022-06-30 | €0.51 | €0.47 | x |
| 2023-06-30 | €0.25 | €0.47 | x |
| 2024-06-30 | €0.13 | €0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PERRIGO utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -167.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3055.68%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.99x
- Recent ROE (-167.93%) is below the historical average (-105.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -99.99% | -11535.30% | 0.00x | 2.06x | €-9.40 Million |
| 2022 | -43.53% | -156281.95% | 0.00x | 1.12x | €-19.22 Million |
| 2023 | -111.23% | -4258.71% | 0.02x | 1.18x | €-31.70 Million |
| 2024 | -167.93% | -3055.68% | 0.03x | 1.99x | €-43.90 Million |
Industry Comparison
This section compares PERRIGO's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $12,331,001,067
- Average return on equity (ROE) among peers: -14.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PERRIGO (PGO) | €13.29 Million | -99.99% | 1.43x | $6.37K |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.67 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $139.89 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $17.08 Million |